Top investors say Kymera Therapeutics Inc. (KYMR) ticks everything they need

Kymera Therapeutics Inc. (NASDAQ: KYMR) stock jumped 5.55% on Friday to $35.00 against a previous-day closing price of $33.16. With 0.58 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.78 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $35.11 whereas the lowest price it dropped to was $33.16. The 52-week range on KYMR shows that it touched its highest point at $46.22 and its lowest point at $13.15 during that stretch. It currently has a 1-year price target of $55.62.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of KYMR was up-trending over the past week, with a rise of 4.23%, but this was up by 32.63% over a month. Three-month performance surged to 46.08% while six-month performance rose 53.85%. The stock lost -9.65% in the past year, while it has gained 40.22% so far this year. A look at the trailing 12-month EPS for KYMR yields -2.94 with Next year EPS estimates of -2.73. For the next quarter, that number is -0.63. This implies an EPS growth rate of -70.00% for this year and 7.20% for next year.

Float and Shares Shorts:

At present, 54.54 million KYMR shares are outstanding with a float of 50.98 million shares on hand for trading. On Oct 13, 2022, short shares totaled 7.7 million, which was 14.07% higher than short shares on Sep 14, 2022. In addition to Dr. Bruce L. Booth D.Phil., DPHIL, Ph.D. as the firm’s Co-Founder & Chairman, Dr. Nello Mainolfi M.D., Ph.D. serves as its Co-Founder, Pres, CEO & Director.

Institutional Ownership:

Through their ownership of 96.49% of KYMR’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 40.80% of KYMR, in contrast to 40.23% held by mutual funds. Shares owned by individuals account for 19.61%. As the largest shareholder in KYMR with 7.62% of the stake, BVF Partners LP holds 4,179,765 shares worth 4,179,765. A second-largest stockholder of KYMR, T. Rowe Price Associates, Inc., holds 4,097,712 shares, controlling over 7.47% of the firm’s shares. Wellington Management Co. LLP is the third largest shareholder in KYMR, holding 3,410,386 shares or 6.22% stake. With a 4.36% stake in KYMR, the T Rowe Price New Horizons Fund is the largest stakeholder. A total of 2,392,843 shares are owned by the mutual fund manager. The SPDR S&P Biotech ETF, which owns about 3.85% of KYMR stock, is the second-largest Mutual Fund holder. It holds 2,114,531 shares valued at 52.78 million. Vanguard Explorer Fund holds 2.24% of the stake in KYMR, owning 1,229,527 shares worth 30.69 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for KYMR since 18 analysts follow the stock currently. There are 12 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 6 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With KYMR analysts setting a high price target of $93.00 and a low target of $31.00, the average target price over the next 12 months is $55.63. Based on these targets, KYMR could surge 165.71% to reach the target high and fall by -11.43% to reach the target low. Reaching the average price target will result in a growth of 58.94% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. KYMR will report FY 2022 earnings on 02/22/2024. Analysts have provided yearly estimates in a range of -$1.73 being high and -$3.31 being low. For KYMR, this leads to a yearly average estimate of -$2.90. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Kymera Therapeutics Inc. surprised analysts by -$0.03 when it reported -$0.79 EPS against a consensus estimate of -$0.76. The surprise factor in the prior quarter was -$0.09. Based on analyst estimates, the high estimate for the next quarter is $0.39 and the low estimate is -$0.92. The average estimate for the next quarter is thus -$0.63.

Summary of Insider Activity:

Insiders traded KYMR stock several times over the past three months with 2 Buys and 48 Sells. In these transactions, 47,500 shares were bought while 1,781,924 shares were sold. The number of buy transactions has increased to 37 while that of sell transactions has risen to 48 over the past year. The total number of shares bought during that period was 1,718,259 while 1,781,924 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *